目的 探讨不同时期阿霉素肾病大鼠尿液中Fractalkine表达的变化及白介素18结合蛋白(IL-18BP)的治疗作用.方法建立阿霉素肾病大鼠模型,设立肾病组(n=12)、IL-18BP干预组(n=11)和对照组(n=10).观察42 d,定期检测大鼠尿Fractalkine水平及24h尿蛋白定量.结果 肾病组和IL-18BP干预组大鼠尿Fractalkine水平均进行性提高,差异有统计学意义(F=91.395、47.248,P均＜0.01)；IL- 18BP干预组大鼠各时间点尿Fractalkine水平均低于肾病组(P均＜0.05),高于对照组(P均＜0.01).肾病组、IL-18BP干预组大鼠尿Fractalkine水平与24h尿蛋白定量均呈正相关(r=0.970、0.904,P均＜0.01).结论 Fractalkine与阿霉素肾病大鼠蛋白尿相关,IL-18BP可降低Fractalkine水平,可能有助于微小病变肾病治疗.%Objective To investigate the changes in Fractalkine expression in urine of adriamycin nephropathy rate at different times, and the therapeutic effect of interleukin-18 binding protein. Methods Adriamycin rat model was created, and nephropathy group (n = 12), IL-18BP treatment group (n = 11) and normal control group (n = 10) were set up. Orinary Fractalkine levels in rat urine and 24-hour urinary protein were regularly detected in 42 days. Results Orinary Fractalkine levels in nephropathy group and IL-18BP treatment group were gradually increased and the difference was statistically significant (F = 91.395, 47.248, P < 0.01) ; during the treatment period, Orinary Fractalkine levels in IL-18BP treated group were significantly lower than that in nephropathy group (P < 0.05) , hut was significantly higher than the normal control group (P < 0.01). Urinary Fractalkine levels was significantly positively correlated with 24-hour urinary protein (r = 0.970, P< 0.01). Conclusions Fractalkine levels were correlated with protein-uria in rate with adriamycin nephropathy. IL-18BP can reduce the Fractalkine level, and thus may contribute to the treatment of minimal change nephropathy.
展开▼
